Radiopharmaceuticals in monitoring cancer by unknown
radiological features, together with tumour markers in
122 patients who presented with or developed calcifica-
tion within metastatic ovarian cancer. Changes in soft
tissue lesion size and the development of calcification
have been correlated with histopathology and outcome.
The study group was compared with a control group of
1577 patients who had a CT scan performed at least
once during follow-up. A positive relationship between
calcification and tumour sub-type was identified with
serous tumours, which represented 60% of the calcified
group, against 30% in the control. Patients with calcifi-
cation were generally higher stage than the control
group but lower grade. They also had a poorer survival
rate.
There did not seem to be any relationship between the
development of calcification and chemotherapy and
thus it is unusable as a marker of response. Reliable
assessment of metastatic ovarian cancer still remains
extremely diﬃcult and it is contended that for this
disease trial data should be subjected to external panel
review.
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Introduction
Normal cells have three basic outcomes: diﬀerentiation,
division and death. Cancer cells usually have reduced
diﬀerentiation, increased division and mechanisms to
avoid programmed cell death, apoptosis. These proper-
ties can be used to monitor cancer by nuclear medicine
imaging.
Differentiation
Thyroid cancer cells show a reduced ability to take up
radio-iodine compared with normal cells. Thus, all
normal thyroid tissue has to be ablated surgically and
with radio-iodine in order that the papillary or follicular
thyroid cancers show uptake on radioiodine images and
for thyroglobulin, Tg, to be a useful serum marker.
Monitoring of thyroid cancer used to be done with a
tracer amount of radioiodine 131I. It was found that
administration of amounts greater than 185 MBq, 5 mCi
may cause stunning, reducing the of eﬀectiveness of the
large dose of 131I given for therapy, (5–6 GBq, 150 mCi).
However, 185 MBq (or less) 131I gives a poor count rate
signal, so that weakly iodine-avid malignant disease may
not be detected. If the Tg is raised, some authorities are
giving 131I therapy in the absence of proof of iodine
uptake. Some 50% of such patients show no uptake
Figure 2
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on the post-therapy dose scan. Those patients have
received a large amount of unnecessary radiation,
hospitalization and temporary hypothyroidism while oﬀ
trioiodothyronine. Such practice is against the radiation
rules for the justification of the administration of radio-
active materials to patients. The answer is to monitor
with a dose of the gamma remitting 123I (185 MBq,
5 mCi), which gives a similar count rate as a therapy
dose of 131I, but half the radiation dose of 185 MBq,
5 mCi of 131I. Then there is no stunning, so that iodine-
avid disease can be treated. With this dose of 123I, but
not the trivial doses of 123I used previously of less than
20 MBq, 0.5 mCi, a patient who is negative on 123I is not
treated by radioiodine in spite of a raised Tg. The
eﬀectiveness of this approach in deciding when 131I
therapy is needed has been shown with a Tg-positive,
131I tracer scan-negative, 123I image-positive, 131I post-
therapy scan-positive disease and a Tg-positive, 131I
tracer-negative, 123I image-negative, 131I post-therapy
scan-negative disease. Thus, 123I (185 MBq) and Tg
combination protocols are being introduced to monitor
thyroid cancer[1].
Many neural crest APUDoma tumours maintain
their Uptake-1 mechanism for noradrenaline storage in
chromaﬃn granules. 123I MIBG, metaiodobenzylguana-
dine, a noradrenaline analogue, may be used at an
administered dose of 185 MBq, 5 mCi, to monitor
malignant pheochromocytoma, paragangliomas and
about 50% of abdominal carcinoids. However, usually
once the diagnosis of MIBG-avid tumour is made then
131I MIBG therapy (7.4 GBq, 200 mCi) is given and the
post-therapy scan at 4 days is used to show continuing
MIBG avidity. This therapy is repeated every 6 months
until 45 GBq, 1.2 Ci is given to the patient, or else a
satisfactory response has occurred, or else loss of MIBG
avidity is demonstrated.
Bone metastases usually induce osteoblastic activity,
so serial bone scans may be used to monitor response or
more usually failure of response to treatment. In which
case, evidence of widespread painful bone metastases
from prostate or breast cancer on the bone scan
may indicate the need for therapy with 89Sr or
153Sm-EHTMP Beta-emitting radionuclides.
Division
Cancer cells divide frequently and outgrow normal
tissues partly through better nutrition and partly by
inhibiting the normal environmental reaction to in-
vasion. Better nutrition is achieved by upregulation of
glucose and amino acid transporter proteins. For glu-
cose upregulation of the hexokinase enzyme which phos-
phorylates glucose also occurs. FDG 18F deoxyglycose is
a non-metabolizable analogue of glucose used with
Positron Emission Tomography (PET) imaging for the
detection of cancer vs. benign lesions. This is through
the greater visual and measured uptake (SUV, Standard
Uptake Value) and by demonstrating increased glucose
uptake in lymph nodes either that have not regressed to
normal size on CT scan as after chemotherapy of
Hodgkin’s disease, or else in normal size nodes (1 cm or
less on CT or MRI). It is clear that cancer has to be
present in a normal-sized node before it can enlarge it to
a greater than 1 cm diameter. The specificity of FDG
PET (and 67Gallium) is context-dependent, the presence
of cancer (primary or recurrent) indicating uptake in a
node is likely to be due to cancer.
The general approach is that a reduction of FDG
uptake after chemotherapy indicates a response. Such a
reduction in uptake usually precedes a reduction in
tumour size seen radiologically. However, it has to be
remembered that activated white cells are also hungry
for glucose and that dying necrobiotic cells and the
autolytic process are glucose-avid, as are granuloma[2].
An abscess or glandular enlargement due to infection
may be mistakenly called recurrence. Cancer cells in a
tumour mass are not uniform in response. The more
anaplastic the clone of cells, the greater the initial
expected glucose utilization and probably the greater
reduction of uptake after therapy. It is not yet clear
whether the average response of the tumour or the
maximum response should be taken. In monitoring
the response of cancer to chemotherapy using FDG the
problem is further compounded that just as sick patients
do not eat, so sick cells do not feed. Lack of FDG
uptake thus may not equate with death or response to
chemotherapy but with dormancy. In summary, the
reduction of FDG uptake may give a false sense of
benefit and no change of uptake may be due to an active,
potentially beneficial inflammatory response rather than
a lack of response to the therapy.
There are technical problems in evaluating response
by quantitative imaging, reviewed by Hoekstra et al.[3].
There are no rigorous methods to determine the
threshold to use to draw a region of interest around the
tumour on the image. Say it is 37% of the peak tumour
counts on the pre-treatment image. Should it be 37% on
the post-treatment image, which may be inappropriate
as therapy may have changed the environment as well as
the tumour, or should it be what looks best? In the latter
the subjective element creeps in. Furthermore, the recon-
struction process, whether iterative or back-projection,
relates the count content of each pixel to every other
pixel. The statistical independence of each pixel is lost
and thus the statistical requirement that a comparison
must be made of independent variables is lost. An active
environment, e.g. blood or heart activity will reduce the
count rate in a neighbouring tumour, a stomach bubble
or air in the gut will increase the apparent count rate in
the neighbouring tumour. In principle quantification
should be undertaken before reconstruction, as in the
method called ‘image surgery’[4] . The actual timing of
the second PET scan is a problem in relation to chemo-
therapy and the optimum time to attempt to predict
responsiveness may be diﬀerent for diﬀerent tumours,
diﬀerent regions and diﬀerent patients[5]. It appears that
18F amino acids such as methyl tyrosine (also as 123I
methyl tyrosine) may be more specific, as may radio-
labelled purines and pyramidines, through being less
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aﬀected by the inflammatory response when predict-
ing and monitoring the eﬀect of chemotherapy[6,7].
Nevertheless, FDG PET is being used to monitor breast
cancer therapy successfully[8] and sarcoma[9]. General
recommendations are made by EORTC[10] (Table 1), but
the above caveats need to be noted.
Both Tc-99m SestaMIBI (methoxy-isobutyl isoni-
trile), perhaps representing mitochondrial activity, and
201Thallium, relating to cellular potassium uptake, have
been used to monitor therapeutic response in small cell
lung cancer[11] and in bone and soft tissue tumours[12].
The upregulation of receptors to take advantage of
autocrine growth factors may be imaged with 111In
Octreotide analogues and more recently Tc-99m
Octreotide analogues to monitor somatostatin receptor
avidity in neuro-endocrine tumours. Absence of recep-
tors on imaging will indicate absence of response to cold
Octreotide and to 90Y Dotatoc. The five somatostatin
receptors confound the issue so that an 111Indium
Octreotide-negative scan may be 111Indium Lanreotide-
positive and such a tumour may respond to 90Y Lan-
reotide. As there are over 100 biologically active pep-
tides in the regulation of cell growth and division,
many new radiolabelled peptides are being evaluated for
monitoring cancer.
The architectural disruption of the malignant process
brings antigens normally not exposed to blood to be
upregulated and available for detection by imaging.
Examples are murine and more recently humanized
HMFG, a monoclonal antibody against the human milk
fat globule, and murine and more recently humanized
PR1A3, a monoclonal antibody that binds to colorectal
cancer. Both may be radiolabelled with Tc-99m for
determining recurrent disease and the response to radio
or chemotherapy. Other tumour antigens are upregu-
lated, such as prostate-specific membrane antigen
(PSMA) in prostate cancer which remains fixed to
the cell, unlike the prostate-specific antigen (PSA)
which is increased in the serum. As well as for
judging the operability of primary prostate cancer, anti-
bodies against PSMA-labelled either with 111Indium
(Prostascint) or with Tc-99m may be used after surgery
to judge whether a small change in PSA is significant,
or, if the PSA is rising, the site of the soft tissue
recurrences when the bone scan and other radiology are
negative[13]. Receptor imaging and monoclonal antibody
imaging of antigens present on the cancer cell have the
advantage that these are still present in the dormant
cancer cell during therapy but disappear with successful
treatment. Furthermore, post-surgical or radiotherapy
fibrosis can be distinguished from active or viable
tumour using these agents, which may be diﬃcult with
CT or MRI. When cancer recurs as sheets, ribbons or
plaques with very little mass it is very diﬃcult to detect
it radiologically. The nuclear medicine techniques iden-
tify the presence of cancer through diﬀerences between
the cancer cells and their normal counterparts. Such
identification does not depend on its physical mass.
However, when a more malignant clone of cancer
develops it may lose some receptors and antigens.
Death
Cancers have developed techniques to avoid apoptosis
so that the p53 and related mechanisms fail to recognize
the damaged DNA of the oncogene and thus fail to
switch on the apoptotic mechanism. Treatment of
cancer with chemotherapy and radionuclide therapy
may trigger apoptosis in contrast to high dose external
beam radiotherapy which breaks DNA strands and
tends to cause necrosis. Tc-99m annexin is a marker of
apoptosis. On the onset of apoptosis, phosphatidyl-
serine which is on the inner side of the cell membrane,
becomes exposed to the outer surface where it can
combine with the peptide annexin. Trials have shown
that this imaging agent can demonstrate immunologi-
cally induced apoptosis, for example in cardiac trans-
plant rejection, but so far has been less successful in
demonstrating whether chemotherapy is likely to be
eﬀective or not by imaging before and after the onset of
the first course of chemotherapy. The principle, how-
ever, is a good one and it may be the key to determining
the eﬀectiveness of chemotherapy by demonstrating
activation of apoptosis early in its course[14].
Other approaches include: the demonstration of
hypoxia, for example with radiolabelled nitro-
imidazoles[15,16]; by showing multiple drug resistance or
not as is in Tc-99m-sestaMIBI imaging[17]; and monitor-
ing gene therapy with 123I FIAU or 18F FIAU, a uracil
derivative[18].
Conclusion
The regular and reliable monitoring of cancer therapy
using radiopharmaceutical-based imaging techniques is
Table 1 EORTC 1999 Criteria for FDG response (abridged)
1 Assessment at baseline just before and response at 1–2 weeks after end of chemotherapy cycle
2 Progressive disease (PMD) FDG SUV >25% within tumour RO1 of baseline
3 Stable disease (SMD) FDG SUV <25% 15%
4 Partial response (PMR) FDG SUV decrease of 15–25% after one cycle of chemotherapy or decrease over 25% for more than
one cycle
5 Complete response (CMR) FDG SUV shows complete resolution within the baseline tumour RO1
6 Patlak kinetic approach is preferred. Reproducibility of FDG SUV is required.
FDG, 18F Fluorodeoxyglucose; SUV, Standard Uptake Value.
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still in its infancy, nevertheless, understanding the bio-
logical behaviour of cancer cells undergoing treatment
will lead to one or more of the above approaches
becoming successful.
Monitoring cancer questions
(1) How to detect cancer in lymph nodes less than 1 cm
diameter?
(2) How to relate nuclear medicine imaging and
measurements before, during and after therapy when
the technical assumptions at each image time diﬀer?
(3) What is the best measure for response to therapy
before morphological change?
Is it apoptosis induction or loss of viability, as
reduction in glucose utilisation appears insuﬃcient?
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